Form 4: Outlook Therapeutics Director Awarded Stock Options

Faisal Ghiath Sukhtian, a director of Outlook Therapeutics, received stock options under the company's 2024 Equity Incentive Plan.

Summary

• On October 1, 2024, Faisal Ghiath Sukhtian, a director of Outlook Therapeutics, received stock options.
• He received 56,636 options as an annual grant, 134,430 options under the 2024 Plan, and 19,771 options in lieu of $90,000 in cash fees.
• All options have an exercise price of either $5.22 or $5.25 and expire on October 1, 2034, or October 3, 2034.
• The options vest on October 1, 2025, or in quarterly installments, subject to continuous service, with potential acceleration upon a change in control.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The granting of options is generally viewed as a positive, but it's a routine event.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting requirements incentivize continued service to the company.
• The acceleration of vesting upon a change in control could be seen as a positive for the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice in the pharmaceutical industry.
• The vesting schedules and change-in-control provisions are typical for these types of grants.
• The specific number of options granted and the exercise price would be benchmarked against similar companies in the biotechnology sector, such as Ocular Therapeutix or Aldeyra Therapeutics, considering their market capitalization and stage of development.

Stakeholder Impact

• The granting of stock options could have a minor dilutive effect on existing shareholders.
• The options incentivize the director to work towards increasing shareholder value.

Key Dates